Solvent Evaporator Equipment Supplement to R35GM143101

R35GM143101 溶剂蒸发器设备补充

基本信息

  • 批准号:
    10799251
  • 负责人:
  • 金额:
    $ 5.93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-15 至 2026-07-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT Biodegradable polymers have demonstrated great utility for controlling the release of drugs in vivo, improving drug efficacy, enhancing drug safety, and increasing patient adherence to medication. Unfortunately, current polymers, such as poly(lactic-co-glycolic acid) (PLGA), are not ideal for a number of reasons, despite their well- reported biocompatibility. These materials are generally bulk-degrading materials whose behavior must be empirically determined and offer very little potential for tuning the shape of the cumulative drug release curve other than simply extending or compressing first-order release kinetics. The parent award of this administrative supplement proposal aims to develop new drug delivery systems based on surface-eroding biodegradable polymers that enable full, predictable control over release kinetics, protect encapsulated biologics from environmental stressors that would otherwise diminish their bioactivity, and release multiple drugs in user- defined sequence. This effort requires the synthesis of photo-responsive surface-eroding materials, light-based fabrication to form polymeric microstructures and, in some cases, drug loading using a polymer matrix swelling method. Each of these steps necessitates the use of an organic solvent. Polymerization, photoinitiator distribution, and solvent-mediated drug uptake are performed in solvents, which must be removed prior to in vitro or in vivo evaluation. A solvent evaporator is, by far, the best tool for this job as it works with small reaction vessels, is compatible with viscous materials, and avoids the formation of bubbles that might undermine microparticle morphology. This tool combines the benefits of low pressure, a pre-defined temperature, and centrifugation, which prevents bumping, allowing for the rapid recovery of material with minimal processing losses. The alternatives to a solvent evaporator, which we have recently been forced to employ once our 15- year-old solvent evaporator broke down, are very poor substitutes for the functionality that we lost. A rotary evaporator can—for some polymers and organic solvents—remove the solvent; however, this requires much longer to remove the solvent (sometimes several evaporation cycles with a co-solvent), takes far more time (one sample in one day) to run one sample than it did to run many samples with the solvent evaporator. Additionally, a large quantity of material is lost during transfer and evaporation, which is particularly unfortunate because of the precious nature of our custom-synthesized, surface-eroding polymer. This proposal seeks the financial support necessary to purchase a new solvent evaporator—an SP Genevac EZ-2.4 ELITE evaporator system. This piece of equipment will be able to restore the function that we lost when our previous tool became inoperable while also enhancing our capabilities by enabling the evaporation of organic solvents with high boiling points, such as dimethyl sulfoxide (DMSO; boiling point, 189 °C). We have previously identified DMSO to be a good candidate for drug loading into polymers using the swelling method, but have avoided it due to removal concerns.
项目总结/摘要 可生物降解的聚合物已被证明在控制药物在体内的释放、改善生物相容性和生物相容性方面具有很大的实用性。 药物功效、增强药物安全性和增加患者对药物的依从性。不幸的是,目前 聚合物,如聚(乳酸-共-乙醇酸)(PLGA),由于多种原因不是理想的,尽管它们具有良好的- 报告了生物相容性。这些材料通常是本体降解材料,其行为必须是可降解的。 并且提供很少的调整累积药物释放曲线形状的可能性 而不是简单地延长或压缩一级释放动力学。本行政裁决的父裁决 一项补充提案旨在开发基于表面侵蚀可生物降解的新药物递送系统 能够完全、可预测地控制释放动力学的聚合物, 环境应激源,否则会降低其生物活性,并在用户中释放多种药物, 定义序列。这项工作需要合成光响应表面侵蚀材料,光基 制造以形成聚合物微结构,以及在某些情况下,使用聚合物基质溶胀的药物负载 法这些步骤中的每一个都需要使用有机溶剂。聚合,光引发剂 药物分布和溶剂介导的药物摄取在溶剂中进行,这些溶剂必须在体外释放之前除去。 或体内评价。溶剂蒸发器是迄今为止最好的工具,因为它的工作与小反应 容器,与粘性材料相容,并避免形成气泡, 微粒形态该工具结合了低压、预定义温度和 离心分离,防止碰撞,允许以最少的处理快速回收材料 损失溶剂蒸发器的替代品,我们最近被迫使用,一旦我们的15- 一年前的溶剂蒸发器坏了,是我们失去的功能的非常差的替代品。旋转 对于某些聚合物和有机溶剂,蒸发器可以除去溶剂;然而,这需要很大的 除去溶剂的时间更长(有时用共溶剂进行几个蒸发循环),需要更多的时间(一个 一天中的样品)来运行一个样品比用溶剂蒸发器来运行许多样品所做的要少。此外,本发明还 在转移和蒸发过程中损失了大量的材料,这是特别不幸的,因为 我们定制合成的表面腐蚀聚合物的珍贵特性。该提案寻求财政 购买新溶剂蒸发器-SP Genevac EZ-2.4 ELITE蒸发器系统所需的支持。 这件设备将能够恢复功能,我们失去了当我们以前的工具变得无法操作 同时还通过使具有高沸点的有机溶剂蒸发来增强我们的能力, 例如二甲基亚砜(DMSO;沸点,189 °C)。我们以前已经确定DMSO是一种良好的 使用溶胀方法将药物负载到聚合物中的候选物,但由于去除问题而避免了它。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kevin James McHugh其他文献

Kevin James McHugh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kevin James McHugh', 18)}}的其他基金

Research Supplement to Promote Diversity: Carlos Torres (R03EB031495 Parent Award)
促进多样性的研究补充:Carlos Torres(R03EB031495 家长奖)
  • 批准号:
    10592146
  • 财政年份:
    2022
  • 资助金额:
    $ 5.93万
  • 项目类别:
Research Supplement to Promote Diversity: Belvi Bwela (R03EB031495 Parent Award)
促进多样性的研究补充:Belvi Bwela(R03EB031495 家长奖)
  • 批准号:
    10592142
  • 财政年份:
    2022
  • 资助金额:
    $ 5.93万
  • 项目类别:
Electrosprayed Core-Shell Microparticles as a Pulsatile Vaccine Delivery Platform
电喷雾核壳微粒作为脉冲疫苗输送平台
  • 批准号:
    10195135
  • 财政年份:
    2021
  • 资助金额:
    $ 5.93万
  • 项目类别:
Next-Generation Parenteral Drug Delivery Systems for Controlling Pharmacokinetics
用于控制药代动力学的下一代肠外给药系统
  • 批准号:
    10277139
  • 财政年份:
    2021
  • 资助金额:
    $ 5.93万
  • 项目类别:
Electrosprayed Core-Shell Microparticles as a Pulsatile Vaccine Delivery Platform
电喷雾核壳微粒作为脉冲疫苗输送平台
  • 批准号:
    10372138
  • 财政年份:
    2021
  • 资助金额:
    $ 5.93万
  • 项目类别:
Next-Generation Parenteral Drug Delivery Systems for Controlling Pharmacokinetics
用于控制药代动力学的下一代肠外给药系统
  • 批准号:
    10890222
  • 财政年份:
    2021
  • 资助金额:
    $ 5.93万
  • 项目类别:
Research Supplement to Promote Diversity: Mei-Li Laracuente (1R35GM143101 Parent Award)
促进多样性的研究补充:Mei-Li Laracuente(1R35GM143101家长奖)
  • 批准号:
    10631614
  • 财政年份:
    2021
  • 资助金额:
    $ 5.93万
  • 项目类别:
Next-Generation Parenteral Drug Delivery Systems for Controlling Pharmacokinetics
用于控制药代动力学的下一代肠外给药系统
  • 批准号:
    10488240
  • 财政年份:
    2021
  • 资助金额:
    $ 5.93万
  • 项目类别:
Next-Generation Parenteral Drug Delivery Systems for Controlling Pharmacokinetics
用于控制药代动力学的下一代肠外给药系统
  • 批准号:
    10667652
  • 财政年份:
    2021
  • 资助金额:
    $ 5.93万
  • 项目类别:
Biomaterial Strategies for Modulating the Immune Response
调节免疫反应的生物材料策略
  • 批准号:
    10232052
  • 财政年份:
    2020
  • 资助金额:
    $ 5.93万
  • 项目类别:

相似海外基金

A Longitudinal Qualitative Study of Fentanyl-Stimulant Polysubstance Use Among People Experiencing Homelessness (Administrative supplement)
无家可归者使用芬太尼兴奋剂多物质的纵向定性研究(行政补充)
  • 批准号:
    10841820
  • 财政年份:
    2023
  • 资助金额:
    $ 5.93万
  • 项目类别:
Proton-secreting epithelial cells as key modulators of epididymal mucosal immunity - Administrative Supplement
质子分泌上皮细胞作为附睾粘膜免疫的关键调节剂 - 行政补充
  • 批准号:
    10833895
  • 财政年份:
    2023
  • 资助金额:
    $ 5.93万
  • 项目类别:
Administrative Supplement: Life-Space and Activity Digital Markers for Detection of Cognitive Decline in Community-Dwelling Older Adults: The RAMS Study
行政补充:用于检测社区老年人认知衰退的生活空间和活动数字标记:RAMS 研究
  • 批准号:
    10844667
  • 财政年份:
    2023
  • 资助金额:
    $ 5.93万
  • 项目类别:
StrokeNet Administrative Supplement for the Funding Extension
StrokeNet 资助延期行政补充文件
  • 批准号:
    10850135
  • 财政年份:
    2023
  • 资助金额:
    $ 5.93万
  • 项目类别:
2023 NINDS Landis Mentorship Award - Administrative Supplement to NS121106 Control of Axon Initial Segment in Epilepsy
2023 年 NINDS 兰迪斯指导奖 - NS121106 癫痫轴突初始段控制的行政补充
  • 批准号:
    10896844
  • 财政年份:
    2023
  • 资助金额:
    $ 5.93万
  • 项目类别:
Biomarkers of Disease in Alcoholic Hepatitis Administrative Supplement
酒精性肝炎行政补充剂中疾病的生物标志物
  • 批准号:
    10840220
  • 财政年份:
    2023
  • 资助金额:
    $ 5.93万
  • 项目类别:
Administrative Supplement: Improving Inference of Genetic Architecture and Selection with African Genomes
行政补充:利用非洲基因组改进遗传结构的推断和选择
  • 批准号:
    10891050
  • 财政年份:
    2023
  • 资助金额:
    $ 5.93万
  • 项目类别:
Power-Up Study Administrative Supplement to Promote Diversity
促进多元化的 Power-Up 研究行政补充
  • 批准号:
    10711717
  • 财政年份:
    2023
  • 资助金额:
    $ 5.93万
  • 项目类别:
Administrative Supplement for Peer-Delivered and Technology-Assisted Integrated Illness Management and Recovery
同行交付和技术辅助的综合疾病管理和康复的行政补充
  • 批准号:
    10811292
  • 财政年份:
    2023
  • 资助金额:
    $ 5.93万
  • 项目类别:
Administrative Supplement: Genome Resources for Model Amphibians
行政补充:模型两栖动物基因组资源
  • 批准号:
    10806365
  • 财政年份:
    2023
  • 资助金额:
    $ 5.93万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了